Ecosistema profesional

Esta app en versión completa y las demás en versión demo para probarlas gratis. Las claves se activan por app.

Historia Clínica CaVeSal® — versión completa

Activá tu clave o adquirí la versión completa

Comprar con tarjeta ↗Comprar por transferencia ↗

Calculadora Prenatal CaVeSal® (demo)

Riesgo prenatal, biometría, curvas y más de 40 módulos clínicos.

Emergencias Obstétricas CaVeSal® (demo)

Código Rojo, Código Azul THAE, Código Amarillo — Sepsis, Código Azul Obstétrico y partograma, con modo voz.

CaVeSal® IA

Agente clínico con guías FMF, ACOG, FIGO, NICE y OMS.

CaVeSal® IA se compra sola. No necesitás la versión completa de ninguna app: le escribís tu caso o tu duda y te responde con las guías. Si usás las versiones completas de la Calculadora o la Historia Clínica, le enviás el caso con un toque.Adquirir CaVeSal® IA ↗

CaVeSal® Academy

Todas las guías CaVeSal®, con buscador científico, en 3 idiomas.

La versión completa incluye acceso a CaVeSal® Academy. CaVeSal® Academy es la biblioteca de referencia clínica del ecosistema CaVeSal®. Reúne en un solo lugar las guías clínicas completas de la Calculadora Prenatal, la Historia Clínica y Emergencias Obstétricas, con un buscador común para encontrarlas. Suma atlas médicos (IETA, IOTA, O-RADS, MUSA), clasificaciones y tablas de consulta, y una biblioteca con enlaces a libros y artículos de acceso libre. También tiene una búsqueda que te lleva directo a PubMed y Consensus. Se abre desde un botón dentro de la app.

Tutoriales y activación

Guías paso a paso para sacarle el máximo provecho a cada app.

Autor clínico

Dr. Carlos Vera Salerno

Formación en Medicina Materno-Fetal. Metodología FMF/Nicolaides y guías: ACOG, FIGO, NICE, IADPSG, ATA, WHO, EBCOG, Medicina Fetal Barcelona.

• Título de grado Médico y Cirujano (Paraguay) con homologación al título de grado español Licenciado en Medicina.
• Especialista en Ginecología y Obstetricia.
• Postgrados en Ecografía General y Gineco-Obstétrica, Endocrinología Ginecológica y Reproductiva, Didáctica en Educación Superior y Salud Pública.
• Formación en Inteligencia Artificial y herramientas digitales emergentes aplicadas a la práctica profesional.
• Capacitador Nacional en Salud Sexual y Reproductiva, Código Rojo y Atención Prenatal.
• Miembro del Comité Técnico Nacional de Inmunización (Paraguay).
• Docente universitario de grado y posgrado en Ginecología y Obstetricia, Ecografía, Endocrinología Ginecológica y Reproductiva.
• Miembro del Comité Científico de FLASOG (2024–2026).
• Miembro de Sociedades Científicas en Paraguay (FPGO, SOGON, SOGIA, SODIAP y SEGIRP).
• Presidente de la FPGO (2023–2026).

Aviso legal

El software, el diseño, la interfaz, los textos, los gráficos y la lógica de esta aplicación son propiedad de Dr. Carlos Vera Salerno y están protegidos por la Ley N.º 1328/1998 de Paraguay y los tratados internacionales aplicables (Convenio de Berna). CaVeSal® es una marca registrada. Queda prohibido copiar, reproducir, distribuir, modificar, descompilar, realizar ingeniería inversa, divulgar por cualquier medio, o crear obras derivadas de esta aplicación o de cualquiera de sus componentes, total o parcialmente, sin autorización previa y por escrito del titular. Cualquier uso no autorizado podrá dar lugar a las acciones legales correspondientes.

Referencias bibliográficas

Fuentes citadas a lo largo de las guías de referencia de esta Historia Clínica.

1. Centro Latinoamericano de Perinatología (CLAP) – OPS/OMS. Historia Clínica Perinatal.
2. World Health Organization (WHO). WHO recommendations on antenatal care for a positive pregnancy experience. 2016.
3. Ministerio de Salud Pública y Bienestar Social (MSPyBS), Paraguay. Guía Nacional de Atención Prenatal. 2022.
4. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletins.
5. International Federation of Gynecology and Obstetrics (FIGO). Safe Motherhood Guidelines.
6. National Institute for Health and Care Excellence (NICE). Antenatal care. NG201. 2021.
7. American Thyroid Association (ATA). Guidelines for the Diagnosis and Management of Thyroid Disease in Pregnancy. 2017.
8. Centers for Disease Control and Prevention (CDC). Maternal Immunization Guidelines.
9. Federación Latinoamericana de Sociedades de Obstetricia y Ginecología (FLASOG).
10. Cochrane Database of Systematic Reviews — suplementación en el embarazo (calcio, hierro, ácido fólico).
11. Figueras F. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. EJOGR, 2008.
12. Medicina Fetal Barcelona. Protocolo de crecimiento fetal — noviembre 2024.
13. ISUOG. Delphi Consensus on the definition of fetal growth restriction. 2020.
14. Ministerio de Salud Pública y Bienestar Social (MSPyBS), Paraguay. Guías Nacionales de Prevención de Cáncer de Cuello Uterino. Decreto N° 238/2024.
15. Congreso Nacional del Paraguay. Ley N.º 5777/2016 de protección integral a las mujeres contra toda forma de violencia, y Decreto reglamentario N.º 6973/2017.
16. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin 179 — Breast Cancer Risk Assessment and Screening in Average-Risk Women (actualización 2024).
17. International Society for the Study of Hypertension in Pregnancy (ISSHP). Classification, diagnosis and management recommendations for hypertensive disorders of pregnancy. 2021.
18. Council on Patient Safety in Women's Health Care. Consensus Bundle on Severe Hypertension in Pregnancy and Postpartum. 2017.
19. American Heart Association / American College of Cardiology (AHA/ACC) — marcos de manejo de lípidos · National Lipid Association. 2024.
20. Ministerio de Salud (MINSAL), Chile. Guía Perinatal — Colestasis Intrahepática del Embarazo. 2015.
21. Royal College of Obstetricians and Gynaecologists (RCOG). Intrahepatic Cholestasis of Pregnancy — Green-top Guideline. 2024.
22. Society for Maternal-Fetal Medicine (SFMFM) — recomendaciones sobre colestasis intrahepática del embarazo.
23. European Association for the Study of the Liver (EASL) — guías sobre enfermedad hepática colestásica.
24. Williamson C, et al. Intrahepatic cholestasis of pregnancy. The Lancet. 2018.
25. Ovadia C, et al. Association of adverse perinatal outcomes with intrahepatic cholestasis of pregnancy. The Lancet. 2019.
26. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infections Treatment Guidelines. 2021.
27. Monif GRG. Infectious Diseases in Obstetrics and Gynecology — Clasificación de Enfermedad Inflamatoria Pélvica.
28. Teede H, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Monash University.
29. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004.
30. Van den Bosch T, et al. Terms, definitions and measurements for describing sonographic features of myometrium and uterine masses (MUSA Consensus). Ultrasound Obstet Gynecol. 2015.
31. ESHRE Guideline: Endometriosis. European Society of Human Reproduction and Embryology. 2022.
32. Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding. Int J Gynecol Obstet. 2018.
33. Persu C, et al. Pelvic Organ Prolapse Quantification System (POP-Q). 2011.
34. International Continence Society / International Consultation on Incontinence (ICI-ICS) Guidelines. 2017.
35. American Urological Association / Society of Urodynamics (AUA/SUFU). Guidelines on Stress Urinary Incontinence y Overactive Bladder. 2015/2023.
36. The North American Menopause Society (NAMS). Position Statement on Hormone Therapy. 2022.
37. Heinemann LAJ, et al. The Menopause Rating Scale (MRS). Health and Quality of Life Outcomes. 2004.
38. National Osteoporosis Foundation / Bone Health & Osteoporosis Foundation (NOF/BHOF). Clinician's Guide to Prevention and Treatment of Osteoporosis. 2022.
39. American Association of Clinical Endocrinology (AACE/ACE). Postmenopausal Osteoporosis Guidelines. 2020.
40. World Health Organization (WHO). Medical Eligibility Criteria for Contraceptive Use. 5ª ed. 2015.
41. Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria for Contraceptive Use. 2016.
42. American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 736. 2018.
43. Practice Committee of the American Society for Reproductive Medicine (ASRM). Current evaluation of amenorrhea. Fertility and Sterility. 2015.
44. AACE/ACE Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity.
45. Endocrine Society. Practice Guideline on Pharmacological Management of Obesity.
46. FIGO Statement on Obesity in Pregnancy and Reproductive Health.
47. SURMOUNT y STEP Clinical Trial Studies (Semaglutida y Tirzepatida).
48. International Society for the Study of Women's Sexual Health (ISSWSH). Consensus Guidelines on Testosterone Therapy for Women. 2019.
49. The North American Menopause Society (NAMS). Position Statement on the Management of Genitourinary Syndrome of Menopause. 2020.
50. American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 141. 2019.
51. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility. 9ª ed. 2019.
52. Mihm M, Gangooly S, Muttukrishna S. The normal menstrual cycle in women. Animal Reproduction Science. 2011.
53. ASRM Committee Opinion — Female Infertility Evaluation. 2021.
54. World Health Organization (WHO). Laboratory Manual for the Examination and Processing of Human Semen. 6ª ed. 2021.
55. ASRM/ESHRE Guidelines on Male Infertility Workup.
56. U.S. Preventive Services Task Force (USPSTF). Folic Acid Supplementation Recommendation Statement. 2023.
57. American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 762. 2019.
58. World Health Organization (WHO). Guideline for the Prevention, Diagnosis, and Treatment of Infertility. 2025.
59. ASRM Committee Opinion — Use of clomiphene citrate and letrozole for ovulation induction. Fertility and Sterility. 2020.
60. ESHRE Guideline: Ovulation Induction in PCOS. 2023.
61. Endocrine Society Clinical Practice Guideline. Melmed S, et al. Diagnosis and Treatment of Hyperprolactinemia. 2011.
62. Vilar L, et al. Management of prolactinomas. Neuroendocrinology. 2019.
63. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease. 2020.
64. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update — FIGO Guidelines. 2021.
65. American College of Radiology (ACR). BI-RADS Atlas. 5ª ed. 2013.
66. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 223. 2020.
67. U.S. Preventive Services Task Force (USPSTF). Breast Cancer Screening Recommendation. 2024.
68. Andreotti RF, et al. O-RADS US Risk Stratification and Management System. ACR. 2020.
69. Timmerman D, et al. IOTA Group Simple Rules Consensus. 2008 y 2016.
70. ESGO/ISUOG/IOTA/ESR Consensus Statements on Preoperative Diagnosis of Ovarian Tumors. 2021.
71. ACOG Practice Bulletin No. 171 — Management of Preterm Labor. 2016 (reafirmado 2022).
72. NICE Guideline NG25 — Preterm labour and birth. 2019 (actualizado 2022).
73. FIGO Recommendations on Preterm Birth. 2021.
74. ACOG Practice Bulletin No. 217 — Prelabor Rupture of Membranes. 2020.
75. Ubom AE, Vatish M, Barnea ER; FIGO. FIGO good practice recommendations for preterm labor and preterm prelabor rupture of membranes. Int J Gynaecol Obstet 2023;163(Suppl 2):40-50..
76. Cowles T, et al. Comparison of Indigo Carmine and Methylene Blue dye for amniocentesis dye test. Obstetrics & Gynecology. 1993.
77. ACOG Practice Bulletin No. 189 — Nausea and Vomiting of Pregnancy. 2018 (reafirmado 2021).
78. Koren G, et al. Validation of the Pregnancy-Unique Quantification of Emesis (PUQE) scoring system. 2002, 2005.
79. Royal College of Obstetricians and Gynaecologists (RCOG). Green-top Guideline No. 69 — Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum. 2016.
80. Khalil A, et al. ISUOG Practice Guidelines: performance of third-trimester obstetric ultrasound scan. Ultrasound Obstet Gynecol 2024;63(1):131-147.
81. Society for Maternal-Fetal Medicine (SMFM) Consult Series #46 — Evaluation and management of polyhydramnios. Am J Obstet Gynecol 2018;219(4):B2-B8 (reafirmado 2024).
82. ACOG Practice Bulletin No. 229 — Antepartum Fetal Surveillance. Obstet Gynecol 2021;137(6):e116-e127.
83. Phelan JP, et al. Amniotic fluid volume assessment with the four-quadrant technique at 36-42 weeks' gestation. J Reprod Med 1987;32(7):540-542.
84. Carel JP, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. 2009 (reafirmado 2020).
85. Lawson Wilkins Pediatric Endocrine Society (LWPES) Guidelines.
86. Ministerio de Salud Pública y Bienestar Social (MSPyBS Paraguay). Manual de Atención Integral a Víctimas de Violencia Sexual y de Género.
87. CDC Sexually Transmitted Infections Treatment Guidelines: Sexual Assault Protocols. 2021.
88. World Health Organization (WHO). Guidelines for Medico-Legal Care for Victims of Sexual Violence.
89. Ministerio de Salud Pública y Bienestar Social (MSPyBS Paraguay). Guía de Manejo de la Hemorragia Posparto: Código Rojo Obstétrico. 2ª ed. Resolución S.G. N° 2004/2021.
90. Ministerio de Salud Pública y Bienestar Social (MSPyBS Paraguay). Manual de Cuidados Perinatales. Resolución S.G. N° 1078/2022.
91. Ministerio de Salud Pública y Bienestar Social (MSPyBS Paraguay). Orientaciones Técnicas para la Atención Integral a la Mujer en Climaterio. Resolución S.G. N° 267/2023.
92. Ministerio de Salud Pública y Bienestar Social (MSPyBS Paraguay). Manual Nacional de Normas de Atención de Patologías Ginecológicas. Resolución S.G. N° 050/2025.
93. American Heart Association (AHA) / Universidad de Antioquia / Organización Panamericana de la Salud (OPS). Manejo del antídoto de calcio en toxicidad por sulfato de magnesio.
94. Speiser PW, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency. Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018.
95. Latronico AC, Brito VN, Carel JC. Causes, diagnosis, and treatment of central precocious puberty. The Lancet Diabetes & Endocrinology. 2016.
96. Badouraki M, et al. Evaluation of pelvic ultrasonography in the diagnosis and follow-up of girls with precocious puberty. Journal of Clinical Ultrasound. 2008.
97. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2ª ed. Stanford University Press. 1959.
98. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Archives of Disease in Childhood. 1969.
99. Manning FA, Platt LD, Sipos L. Antepartum fetal evaluation: development of a fetal biophysical profile score. American Journal of Obstetrics and Gynecology. 1980.
100. Ayres-de-Campos D, Spong CY, Chandraharan E, FIGO Intrapartum Fetal Monitoring Expert Consensus Panel. FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography. Int J Gynecol Obstet. 2015.
101. Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. New England Journal of Medicine. 2000.
102. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 216 — Macrosomia. 2020.
103. International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). Practice Guidelines: intrapartum ultrasound. 2018.
104. Leone FP, Timmerman D, Bourne T, et al. Terms, definitions and measurements to describe sonographic features of the endometrium — IETA consensus. Ultrasound Obstet Gynecol. 2010.
105. Epstein E, Fischerova D, Valentin L, et al. Ultrasound characteristics of endometrial cancer as defined by IETA consensus. Ultrasound Obstet Gynecol. 2018.
106. American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 734 — Transvaginal Ultrasonography of the Endometrium in Postmenopausal Bleeding. 2018.
107. Revised American Society for Reproductive Medicine (rASRM). Classification of endometriosis: 1996. Fertility and Sterility. 1997.
108. Keckstein J, Saridogan E, Ulrich UA, et al. The #Enzian classification: deep endometriosis and its associated diseases. Human Reproduction Open. 2021.
109. Bump RC, Mattiasson A, Bø K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. American Journal of Obstetrics and Gynecology. 1996.
110. The North American Menopause Society (NAMS). 2022 Hormone Therapy Position Statement. Menopause. 2022.
111. Stute P, et al. 'Healthy menopause': EMAS 2026 framework for precision, digital, and interdisciplinary midlife health. Maturitas. 2026.
112. Anagnostis P, Bosdou JK, Georgiou T, Goulis DG. Can menopausal hormone therapy be considered in postmenopausal women older than 60 years? Gynecological Endocrinology. 2025.
113. Pratt MC, et al. Fezolinetant for the treatment of vasomotor symptoms associated with menopause. Expert Review of Clinical Pharmacology. 2023.

La mención de estas guías, sociedades científicas o instituciones tiene fines exclusivamente de atribución bibliográfica. Ninguna de ellas patrocina, avala, certifica ni participa en el desarrollo de este software.